Poolbeg Pharma PLC
21 July 2026
Poolbeg Pharma plc
Notice of Allowance received for POLB 001 Cancer Immunotherapy-induced CRS patent in Israel
Continued momentum in Poolbeg's global intellectual property strategy
21 July 2026 - Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received a Notice of Allowance for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") patent application from the Israeli Patent Office.
This positive update follows the decision to grant the patent application in Europe and formal grants in Australia and Canada, representing further progress in the Company's global IP strategy to protect its lead asset, POLB 001, a potentially preventative oral therapy for cancer immunotherapy-induced CRS.
The patent application in Israel covers the use of p38 MAPK inhibitors, including POLB 001, for the prevention of cancer immunotherapy-induced CRS, and is underpinned by proprietary data generated by Poolbeg. The application has now passed examination by the Israeli patent office, and the Board expects it to progress to grant in due course. As the Company advances through clinical development, such IP progress supports the strategic and commercial appeal of the asset to potential partners and reinforces Poolbeg's commitment to building a robust and defensible patent estate around POLB 001.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said: "Continued positive momentum in our global IP strategy is crucial to strengthening POLB 001's intellectual property position. Receiving a Notice of Allowance from the Israeli Patent Office is an important step towards securing full patent protection and reflects the strength of our proprietary data and scientific approach.
"Building a robust and globally protected IP estate remains a core priority for us, thereby enhancing the strategic appeal of POLB 001 as we continue to engage with potential partners. We look forward to securing the full patent grant in due course and continuing to expand protection across key territories worldwide."
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O'Connell, CFO |
+44 (0) 207 183 1499 |
|
Cavendish Capital Markets Ltd (NOMAD & Joint Broker) Geoff Nash, Trisyia Jamaludin (Corporate Finance) Nigel Birks (Life Science Specialist Sales) Harriet Ward (ECM) |
+44 (0) 207 220 0500 |
|
Oak Securities (Joint Broker) Jerry Keen, Calvin Man |
+44 (0) 20 3973 3678 |
|
Shore Capital Stockbrokers Ltd (Joint Broker) David Coaten, Harry Davies-Ball (Corporate Advisory) |
+44 (0) 207 408 4090 |
|
J&E Davy (Joint Broker) Anthony Farrell, Niall Gilchrist |
+353 (0) 1 679 6363 |
|
Optimum Strategic Communications Nick Bastin, Katie Flint, Elena Bates |
+44 (0) 208 078 4357 |
About Poolbeg Pharma plc
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
Stay updated: Website | Sign up for RNS alerts | Presentation | X | LinkedIn
Forward-Looking Statements
This announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Poolbeg's present and future business strategies and the environment in which Poolbeg expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Poolbeg's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Poolbeg's ability to obtain financing, changes in the political, social and regulatory framework in which Poolbeg operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.